|Bid||4.2700 x 0|
|Ask||4.2800 x 0|
|Day's Range||4.1700 - 4.5000|
|52 Week Range||3.6500 - 11.3700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.11|
Cronos Group remains a high-risk, high-reward stock, despite its solid first-quarter performance. The post Is Cronos Group (TSX:CRON) a Buy After its 1st-Quarter Performance? appeared first on The Motley Fool Canada.
TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Office, will speak at two upcoming conferences: Canaccord Genuity's 6th Annual Cannabis Conference (virtual) on Wednesday, May 11, 2022 at 1:30 p.m. ET. BMO’s 17th Annual Global Farm to Market Conference on Thursday, May 19, 2022 at 2:00 p.m. ET. Webcasts wi
Today announced its 2022 first-quarter business results. All numbers are in U.S. dollars. Net revenue ...